Morphine Sulfate; Naltrexone Hydrochloride Patent Expiration
Morphine Sulfate; Naltrexone Hydrochloride is used for management of severe chronic pain through long-term opioid treatment. It was first introduced by Alpharma Pharmaceuticals Llc
Morphine Sulfate; Naltrexone Hydrochloride Patents
Given below is the list of patents protecting Morphine Sulfate; Naltrexone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Embeda | US8623418 | Pharmaceutical composition | Nov 07, 2029 | Alpharma Pharms |
| Embeda | US7815934 | Sequestering subunit and related compositions and methods | Dec 12, 2027 | Alpharma Pharms |
| Embeda | US7682633 | Pharmaceutical composition | Jun 19, 2027 | Alpharma Pharms |
| Embeda | US7682634 | Pharmaceutical compositions | Jun 19, 2027 | Alpharma Pharms |
| Embeda | US8158156 | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist | Jun 19, 2027 | Alpharma Pharms |
| Embeda | US8846104 | Pharmaceutical compositions for the deterrence and/or prevention of abuse | Jun 19, 2027 | Alpharma Pharms |
| Embeda | US8877247 | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist | Jun 19, 2027 | Alpharma Pharms |
| Embeda | US8685443 | Sequestering subunit and related compositions and methods | Jul 03, 2025 | Alpharma Pharms |
| Embeda | US8685444 | Sequestering subunit and related compositions and methods | Jul 03, 2025 | Alpharma Pharms |
Morphine Sulfate; Naltrexone Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List